Franklin Street Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-83,400
| Closed | -$190K | – | 175 |
|
|
2024
Q2 | $190K | Hold |
83,400
| – | – | 0.01% | 162 |
|
|
2024
Q1 | $360K | Hold |
83,400
| – | – | 0.03% | 120 |
|
|
2023
Q4 | $254K | Hold |
83,400
| – | – | 0.02% | 134 |
|
|
2023
Q3 | $120K | Buy |
83,400
+49,000
| +142% | +$94.8K | 0.01% | 147 |
|
|
2023
Q2 | $86K | Buy |
34,400
+1,240
| +4% | +$3.39K | 0.01% | 151 |
|
|
2023
Q1 | $89K | Buy |
33,160
+10,000
| +43% | +$48.1K | 0.01% | 142 |
|
|
2022
Q4 | $126K | Hold |
23,160
| – | – | 0.01% | 140 |
|
|
2022
Q3 | $289K | Hold |
23,160
| – | – | 0.03% | 120 |
|
|
2022
Q2 | $114K | Hold |
23,160
| – | – | 0.01% | 144 |
|
|
2022
Q1 | $176K | Hold |
23,160
| – | – | 0.01% | 151 |
|
|
2021
Q4 | $236K | Buy |
23,160
+2,160
| +10% | +$27.5K | 0.02% | 148 |
|
|
2021
Q3 | $282K | Hold |
21,000
| – | – | 0.02% | 131 |
|
|
2021
Q2 | $461K | Hold |
21,000
| – | – | 0.04% | 115 |
|
|
2021
Q1 | $505K | Buy |
+21,000
| New | +$488K | 0.05% | 108 |
|
|
2020
Q1 | – | Sell |
-8,000
| Closed | -$211K | – | 159 |
|
|
2019
Q4 | $211K | Buy |
+8,000
| New | +$187K | 0.03% | 145 |
|
|
2019
Q3 | – | Sell |
-8,000
| Closed | -$245K | – | 168 |
|
|
2019
Q2 | $245K | Buy |
+8,000
| New | +$168K | 0.03% | 136 |
|
Franklin Street Advisors's GTHX Position: Q3 2024 in Review
Franklin Street Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 83,400 shares — an estimated $190K sold.
Franklin Street Advisors first reported a position in GTHX in Q2 2019 and held it in 16 quarters. The position peaked at $505K in Q1 2021. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Franklin Street Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Franklin Street Advisors sold 83,400 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $190K.
- Franklin Street Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- Franklin Street Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $505K in Q1 2021.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Franklin Street Advisors's 13F filing for Q3 2024, filed 9 Oct 2024.